ModernaRNAModerna gives mRNA oncology a shot in the armA Phase III win for Moderna and Merck’s personalized mRNA cancer vaccine has reignited investor enthusiasm for mRNA — and put BioNTech back in the spotlight. But the data are more important than … more ➔
AstraZeneca plcCancerAnother disappointment: AstraZeneca halts Phase III lung cancer trial for volrustomigAstraZeneca has discontinued a pivotal Phase III trial of its dual checkpoint inhibitor volrustomig in metastatic non-small cell lung cancer (NSCLC), after an independent committee concluded that the … more ➔
Merck KGaAMergerMerck-Bio-Techne: One step closer to fusion, deal clears German antitrust reviewGermany’s Federal Cartel Office has cleared Merck KGaA’s planned acquisition of U.S. life sciences tools company Bio-Techne, removing one of the key regulatory hurdles to the €9.9 billion deal … more ➔
Wikipedia/Ceescamel EMAEurope withdraws Tavneos as AAV treatment and opens a gap for other complement inhibitors?The European Commission has revoked the marketing authorization for Tavneos (avacopan) in ANCA-associated vasculitis, citing unreliable efficacy data from the pivotal ADVOCATE trial and serious liver … more ➔
AgainIndustrial BiomanufacturingCopenhagen-based Again acquires US Geno to connect AI-driven discovery with industrial biomanufacturingThe Copenhagen-based biomanufacturing company is acquiring Genomatica, bringing Geno’s computational biology and industrial biotech expertise into a platform designed to move from pathway discovery … more ➔
TecanLab automationThe emergence of agentic AI in lab automationThere’s uncertainty and concern about whether AI will replace humans in workplaces. But Marco Ravot-Licheri, Head of Digital – Life Sciences Business at Tecan, told us that AI could increase laboratory … more ➔
CDC.govRare diseaseSwiss biotech Vaderis raises $152M to take first HHT-specific therapy into Phase 3Swiss clinical-stage biotech Vaderis Therapeutics has raised $152 million in a Series B round to advance engasertib into Phase 3 for hereditary hemorrhagic telangiectasia (HHT). The financing, backed … more ➔
Mimetas BVOrganoids and Lab-on-chipBruker Takes Majority Stake in dutch MIMETAS as Organoid Technologies Move Into the MainstreamThe U.S. analytical technology group is acquiring a majority stake in Dutch organ-on-a-chip specialist MIMETAS, bringing human tissue models into its broader portfolio of multiomics, spatial biology … more ➔
Knowbio with Sweden.seCancerSwedish kiss for french Innate: Sobi backs Innate’s lacutamab as rare T-cell lymphoma program enters Phase 3Swedish rare-disease specialist Sobi is paying $75 million upfront for global commercial rights to Innate Pharma’s lacutamab, a first-in-class antibody targeting KIR3DL2 in cutaneous T-cell lymphoma. … more ➔
licensingActimed retrieves ALS drug after Faraday collapseUK biotech Actimed Therapeutics has regained global rights to S-oxprenolol from the now-defunct Faraday Pharmaceuticals, giving it control of the experimental muscle-wasting drug across cancer cachexia, … more ➔
Moderna
AstraZeneca plc
Merck KGaA
Wikipedia/Ceescamel 
Again
Tecan
CDC.gov
Mimetas BV
Knowbio with Sweden.se
